<DOC>
	<DOCNO>NCT00853749</DOCNO>
	<brief_summary>The primary purpose study evaluate immune response 13-valent pneumococcal conjugate vaccine ( 13vPnCV ) child infants receive either complete series PnCV versus combination PnCV pneumococcal polysaccharide vaccine ( PSV ) . This study also intend evaluate safety 13vPnC .</brief_summary>
	<brief_title>Immune Response In Children Revaccinated With Pneumococcal Conjugate Vaccine</brief_title>
	<detailed_description>Follow-up measure EMEA support Type II variation Prevenar ( PCV7 ) label</detailed_description>
	<mesh_term>Pneumococcal Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
	<criteria>Fully vaccinate child participate previous Wyeth study ( Study D139P506 ) receive booster dose either 23valent pneumococcal polysaccharide vaccine ( PPV23 ) pneumococcal conjugate vaccine ( PnCV ) per original protocol study . Subjects must good health determine medical history , physical examination clinical judgment . Known allergy component 7valent pneumococcal conjugate vaccine ( 7vPnC ) 13valent pneumococcal conjugate vaccine ( 13vPnC ) . History document invasive pneumococcal disease ( define positive culture S. pneumoniae normally sterile body site ) . Any known suspected disease dysfunction immune system , include : HIV infection , Malignancy , Receipt immunosuppressive therapy , Sickle cell hemoglobinopathy . Receipt immuneglobulin within past 3 month . Receipt either PSV 7vPnCV since completion Study D139P506 .</criteria>
	<gender>All</gender>
	<minimum_age>5 Years</minimum_age>
	<maximum_age>8 Years</maximum_age>
	<verification_date>December 2010</verification_date>
	<keyword>Immune response</keyword>
	<keyword>pneumococcal conjugate vaccine</keyword>
	<keyword>polysaccharide</keyword>
</DOC>